Fluconazole

AAPS PharmSciTech: Cyclodextrin-Crosslinked Poly(Acrylic Acid): Adhesion and Controlled Release of Diflunisal and Fluconazole from Solid Dosage Forms

Type: Original PaperThe controlled release of diflunisal and fluconazole from tablets made of novel polymers, poly(acrylic acid) (PAA) crosslinked with either β-cyclodextrin (βCD) or hydroxypropyl-Î...

Data support flucytosine in HIV-associated meningitis

Initial combination therapy with amphotericin B and flucytosine is associated with fewer deaths among patients with HIV-associated cryptococcal meningitis compared with amphotericin B alone (New Engl...

MethylGene's MGCD290 misses in candidiasis Ph II

MethylGene Inc. (TSX:MYG) said a single oral dose of MGCD290 plus fluconazole missed the primary composite endpoint of improving therapeutic cure rate at day 28 vs. fluconazole alone in the Phase II (...

Cryptococcal Screening and Treatment Saves Money in Africa

Cryptococcal antigen screening and the use of preemptive fluconazole for HIV patients with low CD4 counts is cost effective for health systems in parts of Africa because it prevents meningitis. Meds...

Short Ampho Course Works in Cryptococcus (CME/CE)

(MedPage Today) -- Short-course amphotericin B plus fluconazole (Diflucan) represents an effective means of treating the deadly fungal infection cryptococcal meningitis in countries with few healthcar...

Short-course amphotericin is cost-effective for cryptococcal meningitis

The treatment of cryptococcal meningitis in resource-limited settings is most effective with a short 1-week course of amphotericin induction therapy coupled with high-dose fluconazole for at least 2 w...

MethylGene Presents MGCD290 Data at the 2012 Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)

MONTREAL, QUEBEC, CANADA -- (Marketwire) -- 09/11/12 -- MethylGene Inc. (TSX: MYG) today announced that preclinical data for its novel clinical-stage antifungal, MGCD290, was presented at the 52nd I...

MethylGene Announces Presentation of MGCD290 Phase I Clinical Data at IDWeek(TM) 2012

MONTREAL, CANADA -- (Marketwire) -- 10/22/12 -- MethylGene Inc. (TSX: MYG) today announced that Phase I data for its novel clinical-stage antifungal, MGCD290, were presented at the 2012 IDWeek™ mee...

Level of Evidence for Therapeutic Drug Monitoring of Fluconazole.

Fluconazole is a recommended treatment option for the treatment of invasive candidiasis. Fluconazole is active against most pathogenic Candida spp. except C. kruzei and C. glabrata. Fluconazole is ora...

Cystoid Macular Edema Secondary to Fluconazole Toxicity.

Fluconazole is an antifungal commonly used to treat Coccidioides immitis, but this medication has a number of side effects including fatigue, rash, headache, dizziness, nausea, vomiting, diarrhea, and...

Fluconazole resistance in cryptococcal disease: emerging or intrinsic?

With the widespread use of long-term fluconazole prophylaxis and suppressive treatment, the potential development of fluconazole resistance poses a threat to the management of cryptococcal disease. In...

Efficacy of Fluconazole and Nystatin in the Treatment of Vaginal Candida Species.

The aim of this study was to determine and compare the efficacy of treatment with fluconazole and nystatin in Brazilian women with vaginal Candida. In a population of 932 women, vaginal cultures were...

The effects of combined menthol and borneol on fluconazole permeation through the cornea ex vivo.

The bioavailabilities of eye drops are very low, so it is eager to find a safe and effective penetration enhancer to improve drug bioavailability. In our study, the corneas of New Zealand albino rabbi...